Comparison · NCT02729025-sae
Evolocumab 420 mg QM vs Placebo QM: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Evolocumab 420 mg QM vs Placebo QM: serious adverse events. Trial comparisons, record NCT02729025-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02729025-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0308 | 0.00848 | 0.105 | wilson | |
| Risk in group 2 | 0 | 0 | 0.0566 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0308 | -0.0301 | 0.105 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | log | a group has no participants with the outcome | |||
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | |||
| Number needed to harm, for one more participant with a serious adverse event on Evolocumab 420 mg QM than on Placebo QM | 32.5 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Evolocumab 420 mg QM | Participants received 420 mg evolocumab by subcutaneous injection once a month (QM) for 12 weeks. | 2 | 65 | EG001 |
| Group 2 | Placebo QM | Participants received placebo to evolocumab by subcutaneous injection once a month (QM) for 12 weeks. | 0 | 64 | EG000 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- From the first dose of study drug up to 30 days after the last dose or until the end of study date, whichever was earlier; the maximum duration of treatment was 3.9 months.
Source ClinicalTrials.gov
Trial
- Title
- Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflammation in Patients With Elevated Lipoprotein(a) (Lp(a))
- NCT number
- NCT02729025
- Phases
- PHASE3
- Conditions
- Subjects With Hyperlipidemia, Dyslipidemia
- Interventions
- Evolocumab, Placebo
- Lead sponsor
- Amgen
- Results first posted
- 2019-04-23
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02729025?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02729025-sae